Alex Karnal, a prominent life sciences investor and co-founder of Braidwell, details a transformative shift in medicine from reactive treatment to proactive prevention through a framework called the "health stack." This defensive strategy targets five critical areas: lipid optimization, cardiometabolic health, neurocognitive function, inflammation, and blood pressure. GLP-1 medications serve as a primary catalyst for this revolution, demonstrating massive consumer demand for metabolic health, while PCSK9 inhibitors offer a near "free lunch" for reducing cardiovascular risk by up to 88% in genetically advantaged populations. The integration of AI and robotic automation is accelerating drug discovery by generating novel "science tokens" and shortening the path from hypothesis to molecule. Despite the promise of these breakthroughs, significant barriers remain in cost, complexity, and patient compliance, necessitating a more consumer-centric delivery model to bridge the gap between scientific invention and public health impact.
Sign in to continue reading, translating and more.
Continue
